Sii Investments Inc. WI Has $514,000 Stake in Celgene Corporation (CELG)

Sii Investments Inc. WI decreased its position in shares of Celgene Corporation (NASDAQ:CELG) by 41.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,968 shares of the biopharmaceutical company’s stock after selling 2,841 shares during the quarter. Sii Investments Inc. WI’s holdings in Celgene were worth $514,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Thompson Davis & CO. Inc. raised its stake in shares of Celgene by 5.9% during the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 43 shares in the last quarter. Motco raised its stake in shares of Celgene by 19.3% during the second quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock valued at $127,000 after purchasing an additional 159 shares in the last quarter. Penserra Capital Management LLC bought a new stake in shares of Celgene during the second quarter valued at about $129,000. Acropolis Investment Management LLC bought a new stake in shares of Celgene during the second quarter valued at about $144,000. Finally, Rational Advisors LLC bought a new stake in shares of Celgene during the second quarter valued at about $156,000. 80.17% of the stock is owned by institutional investors.

Several equities research analysts have commented on CELG shares. BMO Capital Markets boosted their price target on shares of Celgene from $148.00 to $155.00 and gave the stock an “outperform” rating in a research report on Friday, November 17th. Oppenheimer reiterated a “buy” rating and issued a $170.00 price target on shares of Celgene in a research report on Friday, October 20th. Vetr upgraded shares of Celgene from a “buy” rating to a “strong-buy” rating and set a $144.39 price target on the stock in a research report on Monday, October 23rd. Cann reiterated a “buy” rating on shares of Celgene in a research report on Thursday, October 26th. Finally, Morgan Stanley upgraded shares of Celgene from an “underweight” rating to an “equal weight” rating in a research report on Friday, October 27th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have assigned a buy rating and two have issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $139.57.

In other Celgene news, insider Terrie Curran sold 1,727 shares of Celgene stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $143.89, for a total transaction of $248,498.03. Following the transaction, the insider now owns 3,925 shares of the company’s stock, valued at approximately $564,768.25. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Gilla Kaplan sold 9,250 shares of Celgene stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total value of $1,309,430.00. Following the transaction, the director now directly owns 85,551 shares in the company, valued at approximately $12,110,599.56. The disclosure for this sale can be found here. Insiders own 0.95% of the company’s stock.

Celgene Corporation (NASDAQ:CELG) opened at $102.17 on Thursday. The firm has a market capitalization of $80,747.23, a PE ratio of 16.02, a P/E/G ratio of 0.79 and a beta of 1.78. Celgene Corporation has a 12 month low of $94.55 and a 12 month high of $147.17. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52.

Celgene (NASDAQ:CELG) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.87 by $0.04. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The firm had revenue of $3.29 billion for the quarter, compared to analysts’ expectations of $3.42 billion. During the same quarter last year, the business posted $1.58 EPS. Celgene’s revenue was up 10.2% on a year-over-year basis. analysts expect that Celgene Corporation will post 6.67 earnings per share for the current fiscal year.

WARNING: This article was first posted by Markets Daily and is owned by of Markets Daily. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.themarketsdaily.com/2017/12/07/sii-investments-inc-wi-has-514000-stake-in-celgene-corporation-celg.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply